Form 4: Neurocrine Biosciences Director George J. Morrow Reports Stock Transactions
SEC Filing
Director George J. Morrow reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.
Summary
- On May 22, 2025, Director George J. Morrow reported transactions involving Neurocrine Biosciences Inc. stock.
- Morrow acquired 3,318 Restricted Stock Units (RSUs) on May 21, 2025, which will vest in full on May 21, 2026.
- Morrow also disposed of 2,869 shares of common stock on May 22, 2025, related to the vesting of previously granted RSUs.
- Following these transactions, Morrow directly owns 3,318 RSUs and 0 shares of common stock.
- The transactions were reported on a Form 4 filing with the SEC.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by SEC regulations. It provides transparency to investors regarding the trading activities of company directors.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of RSU acquisition |
| 05/22/2025 | Date of stock disposal and filing date |
| 05/21/2026 | RSUs will vest in full |
Keywords
Form 4, NBIX, Neurocrine Biosciences, Director, Stock Transaction, Restricted Stock Units, RSU, George J. Morrow, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.